PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjLink to Publisher's site
 
BMJ. 1992 October 17; 305(6859): 913–920.
PMCID: PMC1883560

Low molecular weight heparin in prevention of perioperative thrombosis.

Abstract

OBJECTIVE--To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery. DESIGN--Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. SUBJECTS--Patients who had had general or orthopaedic surgery. INTERVENTION--Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. MAIN OUTCOME MEASURES--Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. RESULTS--The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p < 0.001) and dextran (0.44, 0.30 to 0.65; p < 0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p = 0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p = 0.62). CONCLUSIONS--Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. [PubMed]
  • Cicero R, del Vecchyo C, Porter JK, Carreño J. Open window thoracostomy and plastic surgery with muscle flaps in the treatment of chronic empyema. Chest. 1986 Mar;89(3):374–377. [PubMed]
  • Kakkar VV. Prevention of venous thromboembolism. Clin Haematol. 1981 Jun;10(2):543–582. [PubMed]
  • Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18):1162–1173. [PubMed]
  • Bergqvist D. Dextran in the prophylaxis of deep-vein thrombosis. JAMA. 1987 Jul 17;258(3):324–325. [PubMed]
  • Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl. 1990;556:42–50. [PubMed]
  • Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood. 1982 Jun;59(6):1239–1245. [PubMed]
  • Cade JF, Buchanan MR, Boneu B, Ockelford P, Cater CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res. 1984 Sep 15;35(6):613–625. [PubMed]
  • Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood. 1985 Jan;65(1):198–201. [PubMed]
  • Esquivel CO, Bergqvist D, Björck CG, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res. 1982 Nov 1;28(3):389–399. [PubMed]
  • Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984 Mar 15;218(3):725–732. [PubMed]
  • Lockner D, Bratt G, Törnebohm E, Aberg W. Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers. Haemostasis. 1986;16 (Suppl 2):8–10. [PubMed]
  • Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988 Jul;28(7):609–618. [PubMed]
  • Boissel JP, Bossard N. Registry of multicenter clinical trials. Eleventh report--1989. Thromb Haemost. 1991 Sep 2;66(3):368–383. [PubMed]
  • Boissel JP, Sacks HS, Leizorovicz A, Blanchard J, Panak E, Peyrieux JC. Meta-analysis of clinical trials: summary of an international conference. Eur J Clin Pharmacol. 1988;34(6):535–538. [PubMed]
  • Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet. 1991 Nov 2;338(8775):1127–1130. [PubMed]
  • Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046–1049. [PubMed]
  • Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis. Curr Med Res Opin. 1988;11(2):80–86. [PubMed]
  • Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986 Oct 9;315(15):925–929. [PubMed]
  • Tørholm C, Broeng L, Jørgensen PS, Bjerregaard P, Josephsen L, Jørgensen PK, Hagen K, Knudsen JB. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br. 1991 May;73(3):434–438. [PubMed]
  • Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988 Feb;75(2):128–131. [PubMed]
  • Verardi S, Casciani CU, Nicora E, Forzano F, Origone A, Valle I, Catania G, Salanitri G, Salcuni P, Azzarone M, et al. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Int Angiol. 1988 Jul-Sep;7(3 Suppl):19–24. [PubMed]
  • Bergqvist D, Burmark US, Frisell J, Hallbök T, Lindblad B, Risberg B, Törngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986 Mar;73(3):204–208. [PubMed]
  • Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost. 1986 Dec 15;56(3):243–246. [PubMed]
  • Onarheim H, Lund T, Heimdal A, Arnesjø B. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis. Acta Chir Scand. 1986 Oct;152:593–596. [PubMed]
  • Bergqvist D, Mätzsch T, Burmark US, Frisell J, Guilbaud O, Hallbök T, Horn A, Lindhagen A, Ljungnér H, Ljungström KG, et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg. 1988 Sep;75(9):888–891. [PubMed]
  • Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand. 1988;67(2):99–103. [PubMed]
  • Briel RC, Doller P, Hermann CP. Thromboembolie-Prophylaxe bei Hysterektomien mit dem niedermolekularen Heparin Fragmin. Geburtshilfe Frauenheilkd. 1988 Mar;48(3):160–164. [PubMed]
  • Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemost. 1988 Apr 8;59(2):216–220. [PubMed]
  • Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, Wiesel ML, Kher A, Barbier P, Cazenave JP. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988 Dec;18(6):561–567. [PubMed]
  • Hartl P, Brücke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577–584. [PubMed]
  • Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg. 1985 Oct;72(10):786–791. [PubMed]
  • Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group. Br J Surg. 1991 Apr;78(4):412–416. [PubMed]
  • Schmitz-Huebner U, Bünte H, Freise G, Reers B, Rüschemeyer C, Scherer R, Schulte H, van de Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr. 1984 Apr 16;62(8):349–353. [PubMed]
  • Adolf J, Knee H, Roder JD, van de Flierdt E, Siewert JR. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Abdominalchirurgie. Dtsch Med Wochenschr. 1989 Jan 13;114(2):48–53. [PubMed]
  • Heilmann L, Kruck M, Schindler AE. Thromboseprophylaxe in der Gynäkologie: Doppelblind-Vergleich zwischen niedermolekularem (LMWH) und unfraktioniertem (UFH) Heparin. Geburtshilfe Frauenheilkd. 1989 Sep;49(9):803–807. [PubMed]
  • Sasahara AA, Koppenhagen K, Häring R, Welzel D, Wolf H. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis. Br J Surg. 1986 Sep;73(9):697–700. [PubMed]
  • Baumgartner A, Jacot N, Moser G, Krähenbühl B. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa. 1989;18(2):152–156. [PubMed]
  • Kakkar VV, Stringer MD, Hedges AR, Parker CJ, Welzel D, Ward VP, Sanderson RM, Cooper D, Kakkar S. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. Am J Surg. 1989 Apr;157(4):413–418. [PubMed]
  • Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988 Dec 22;60(3):407–410. [PubMed]
  • Chiapuzzo E, Orengo GB, Ottria G, Chiapuzzo A, Palazzini E, Fusillo M. The use of low molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients. J Int Med Res. 1988 Sep-Oct;16(5):359–366. [PubMed]
  • Pini M, Tagliaferri A, Manotti C, Lasagni F, Rinaldi E, Dettori AG. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Int Angiol. 1989 Jul-Sep;8(3):134–139. [PubMed]
  • Dechavanne M, Ville D, Berruyer M, Trepo F, Dalery F, Clermont N, Lerat JL, Moyen B, Fischer LP, Kher A, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis. 1989;19(1):5–12. [PubMed]
  • Monreal M, Lafoz E, Navarro A, Granero X, Caja V, Caceres E, Salvador R, Ruiz J. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma. 1989 Jun;29(6):873–875. [PubMed]
  • Leyvraz PF, Bachmann F, Hoek J, Büller HR, Postel M, Samama M, Vandenbroek MD. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991 Sep 7;303(6802):543–548. [PMC free article] [PubMed]
  • Haas S, Stemberger A, Fritsche HM, Welzel D, Wolf H, Lechner F, Blümel G. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneimittelforschung. 1987 Jul;37(7):839–843. [PubMed]
  • Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P, Nehen AM, de Carvalho A, Jurik AG, Nielsen BW, et al. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery. Br J Surg. 1988 Jul;75(7):686–689. [PubMed]
  • Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P, Nehen AM, Jurik AG, de Carvalho A, Nielsen BW, et al. Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine. Arch Orthop Trauma Surg. 1989;108(1):10–13. [PubMed]
  • Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg. 1988 Nov;75(11):1053–1057. [PubMed]
  • Mätzsch T, Bergqvist D, Fredin H, Hedner U. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand Suppl. 1988;543:80–84. [PubMed]
  • Hoffmann R, Largiadèr F, Roethlin M. Perioperative Thromboembolie-Prophylaxe: niedrig dosiertes Heparin oder low molecular Heparin-DHE, Vor- und Nachteile. Eine prospektive, randomisierte Untersuchung. Helv Chir Acta. 1987 Dec;54(4):521–525. [PubMed]
  • Collet JP, Boissel JP. Sick population--treated population: the need for a better definition. The VALIDATA Group. Eur J Clin Pharmacol. 1991;41(4):267–271. [PubMed]
  • Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med. 1987 Jan-Feb;6(1):11–29. [PubMed]
  • Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986 Oct;4(10):1529–1541. [PubMed]
  • Dickersin K. Report from the panel on the Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials. Control Clin Trials. 1988 Mar;9(1):76–81. [PubMed]
  • Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991 Apr 13;337(8746):867–872. [PubMed]
  • Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomised clinical trials. Lancet. 1986 Jul 19;2(8499):143–146. [PubMed]
  • Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, Candardjis G. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 1983 Oct 20;309(16):954–958. [PubMed]
  • Taberner DA, Poller L, Thomson JM, Lemon G, Weighill FJ. Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg. 1989 Sep;76(9):933–935. [PubMed]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Group